Top Markets
#1 MowCat MowCat +48.86%
#2 Velvet Velvet +22.01%
#3 Derive Derive +19.45%
#4 Quack AI Quack AI +19.40%
#5 Bermuda Shorts Bermuda Shorts +15.70%
#6 Geodnet Geodnet +15.17%
#7 SkyAI SkyAI +14.51%
#8 aPriori aPriori +13.09%
#9 Audiera Audiera +12.67%
#10 Cross Cross +11.92%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
株式のランク #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
株価
$2.37
最終同期: 2025-12-15
時価総額
$3.99M
変化（1日）
-5.58%
変化（1年）
24.74%
国
US
取引 Qualigen Therapeutics, Inc. (QLGN)

カテゴリー

Healthcare
Qualigen Therapeutics, Inc.（QLGN）の収益
Aug 2026 時点の収益 TTM: 0
Qualigen Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Qualigen Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE